Lisocabtagene Maraleucel

A new retrospective analysis has added to building evidence that suggests chimeric antigen receptor T-cell therapy does not directly cause secondary malignancies.

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.

Historically, Jae H. Park, MD, has not paid much attention to his patients’ weight loss.

Chimeric antigen receptor T-cell therapy can be administered at community centers and on an outpatient basis with proper preparation, education and resources, according to prospective study results.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.

An FDA mandate that requires patients who receive chimeric antigen receptor T-cell therapy to stay within a certain radius of their treatment facility for nearly a month for adverse event monitoring may be overly restrictive.

In a video interview, Matthew Cortese, MD, MPH, discusses how AI could transform the treatment landscape for CLL.

In a video interview, Matthew Cortese, MD, MPH, discusses the importance of long-term monitoring in CLL care.

In a video interview, Matthew Cortese, MD, MPH, discusses strategies to combat infections in CLL patients.